Emerging Therapeutic Modalities and Bioanalytical Strategies
Earn a Certificate of Live Attendance
AI Webinar Explorer available after event
About this webinar
Therapeutic innovation is moving beyond conventional small molecules and monoclonal antibodies toward complex modalities that can engage previously inaccessible biology, overcome resistance and improve drug delivery. These advances create therapeutic opportunities alongside new bioanalytical challenges that influence development strategy, data interpretation and program progression. This webinar explores how emerging therapeutic modalities are reshaping drug development and how effective bioanalytical strategies can help address their unique challenges.
In oncology, antibody-drug conjugates (ADCs) are rapidly evolving beyond single-target, single-payload constructs. Dual-payload ADCs aim to engage complementary cell-killing mechanisms and potentially overcome treatment resistance, while bispecific antibodies can recognize two epitopes or antigens simultaneously. The conjugate landscape also includes degrader-antibody, oligonucleotide-antibody and peptide-antibody conjugates, each introducing unique challenges related to exposure, stability, biotransformation and analyte selection. In parallel, PROTACs and molecular glues are expanding the “undruggable” proteome through targeted degradation of disease-driving proteins, including those associated with c-MYC pathways.
Emerging modalities are also reshaping chronic disease treatment. In autoimmune diseases, peptides and small molecules targeting IL-17, TNF-α, CARD9 and STAT6 may offer oral alternatives to injectable biologics. In obesity, approaches targeting FGF21, GPR61 and related pathways aim to improve gastrointestinal tolerability, lean mass preservation and weight reduction. Targeted protein degradation may also offer new approaches to neurodegenerative diseases, including Parkinson’s, Alzheimer’s, ALS and Huntington’s disease, by removing pathogenic proteins.
As therapeutic modalities become more complex, bioanalysis must evolve with them. Appropriate analyte selection and assays that distinguish intact drug, payload, metabolites, conjugated species or degradation products are essential. This session will examine the scientific principles and practical bioanalytical strategies for emerging modalities, emphasizing LC-MS/MS study-sample analysis.
Register for this webinar to learn how to address bioanalytical challenges associated with emerging therapeutic modalities and strengthen data-driven drug development decisions.
Who should attend
- Bioanalytical & Assay Development Scientists and leaders: Bioanalytical Sciences, LC-MS/MS, Biomarker Development, PK/PD, Immunogenicity and Analytical Method Development
- DMPK, ADME & Clinical Pharmacology teams: Scientists and leaders responsible for drug exposure, metabolism, pharmacokinetics and interpretation of preclinical and clinical data
- Discovery, Translational & Preclinical Scientists: Researchers developing ADCs, targeted protein degraders, peptides, oligonucleotides and other emerging therapeutic modalities
- Drug Development & Outsourcing decision makers: Directors and Executives in Translational Medicine, Clinical Development, R&D, External Innovation, Strategic Outsourcing and CRO/partner management who determine bioanalytical strategy and select external partners
What you will learn
- Understand how emerging therapeutic modalities, including next-generation ADCs, bispecifics, targeted protein degraders and novel conjugates, are expanding the druggable landscape and addressing limitations of existing therapies
- Explore how modality innovation is reshaping therapeutic strategies across oncology, autoimmune diseases, obesity and neurodegenerative disorders
- Identify the unique bioanalytical challenges created by increasingly complex modalities, including selecting the appropriate analyte and assessing exposure, stability, biotransformation and degradation
- Learn how fit-for-purpose LC-MS/MS strategies can generate decision-enabling data, reduce development uncertainty and support the advancement of novel therapeutics
Featured Speaker
Chad Christianson
Chad has over 25 years of related experience as an Analytical Scientist, with over 20 years focused on bioanalysis at Alturas Analytics. This depth of experience in applied LC-MS/MS, LC-HRMS/MS and GC-MS/MS, along with an education in chemical engineering, provides the backbone for productive and innovative science.
As Senior Scientific Advisor, Chad functions as a subject matter expert to support business development and marketing campaigns. He is also responsible for the supervision of the analytical method development team in supporting complex method development, new technology evaluation/implementation and providing technical oversight to clients across all therapeutic areas. Additional responsibility includes acting as Study Director/Principal Investigator on GLP and clinical studies. Chad also provides oversight of Alturas publications and scientific outreach.
Partner for this event
Alturas Analytics
Alturas Analytics is a GLP compliant bioanalytical CRO specializing in LC-MS/MS solutions supporting preclinical and clinical research, IND submissions, and New Drug Applications. In addition to providing PK support services to pharmaceutical companies worldwide, Alturas maintains an intensive research effort to apply new technologies toward scientific advancement. Our success is built on developing long-term relationships with clients by delivering high-quality bioanalytical results in a timely manner.